| Philip Joseph Cheng, MD | |
|
140 Allen Rd, Basking Ridge, NJ 07920-2976 | |
| (908) 495-1183 | |
| Not Available |
| Full Name | Philip Joseph Cheng |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Location | 140 Allen Rd, Basking Ridge, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417290719 | NPI | - | NPPES |
| Entity Name | University Of Utah Adult Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114321981 PECOS PAC ID: 0941525273 Enrollment ID: O20150209001683 |
News Archive
A new study led by scientists at the Sanford Burnham Prebys Medical Discovery Institute describes a technology that could lead to new therapeutics for traumatic brain injuries. The discovery, published today in Nature Communications, provides a means of homing drugs or nanoparticles to injured areas of the brain.
DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.
If you're having trouble getting a date, French researchers suggest that picking the right soundtrack could improve the odds. Women were more prepared to give their number to an 'average' young man after listening to romantic background music, according to research that appears today in the journal Psychology of Music, published by SAGE.
Watson Pharmaceuticals, Inc. today reported net revenue of $1.1 billion for the third quarter ended September 30, 2011, an increase of 23 percent when compared to $882.4 million in the third quarter 2010. On a non-GAAP basis, net income for the third quarter 2011 increased 31 percent to $138.7 million or $1.09 per diluted share, compared to $105.9 million or $0.85 per diluted share in the third quarter 2010.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Philip Joseph Cheng, MD 140 Allen Rd, Basking Ridge, NJ 07920-2976 Ph: (908) 604-7800 | Philip Joseph Cheng, MD 140 Allen Rd, Basking Ridge, NJ 07920-2976 Ph: (908) 495-1183 |
News Archive
A new study led by scientists at the Sanford Burnham Prebys Medical Discovery Institute describes a technology that could lead to new therapeutics for traumatic brain injuries. The discovery, published today in Nature Communications, provides a means of homing drugs or nanoparticles to injured areas of the brain.
DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.
If you're having trouble getting a date, French researchers suggest that picking the right soundtrack could improve the odds. Women were more prepared to give their number to an 'average' young man after listening to romantic background music, according to research that appears today in the journal Psychology of Music, published by SAGE.
Watson Pharmaceuticals, Inc. today reported net revenue of $1.1 billion for the third quarter ended September 30, 2011, an increase of 23 percent when compared to $882.4 million in the third quarter 2010. On a non-GAAP basis, net income for the third quarter 2011 increased 31 percent to $138.7 million or $1.09 per diluted share, compared to $105.9 million or $0.85 per diluted share in the third quarter 2010.
› Verified 9 days ago